View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 57, No. 15, 2011 © 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.037 proposed to improve cardiac risk prediction. Professional EDITORIAL COMMENT organizations have sought to evaluate the literature and distill the available data into a summary form that is succinct and conveniently accessible to the busy clinician: hence, the “Actually, It Is More of guideline. In this issue of the Journal, Ferket et al. (6) present a a Guideline Than a Rule”* systematic review of the guidelines on imaging of asymp- tomatic coronary artery disease (CAD) published by major Roger S. Blumenthal, MD, Rani K. Hasan, MD professional organizations between 2003 and early 2010. The authors based their search on the Institute of Medicine Baltimore, Maryland definition for clinical practice guidelines, and they limited their selections to guidelines that included recommenda- tions for imaging for primary prevention of CAD in In a classic scene from the iconic movie Ghostbusters (1984, presumably healthy nondiabetic populations. They also directed by Ivan Reitman), Dr. Peter Venkman (played by performed an assessment of the guideline generation process Bill Murray) confesses to Dana Barrett (played by Sigourney for each of the included guidelines using the 7-item Rigor of Weaver), “I make it a rule never to get involved with Development domain of the Appraisal of Guidelines Re- possessed people.” However, after Dana starts to seduce search and Evaluation (AGREE) instrument. him, Dr. Venkman replies, “Actually, it is more of a Fourteen guidelines published by the U.S. Preventive guideline than a rule!” Services Task Force (USPSTF), the New Zealand Guide- lines Group (NZGG), the American Heart Association See page 1591 (AHA), the American College of Cardiology Foundation (ACCF), the National Cholesterol Education Program Although 90% to 95% of the global population- (NCEP), the Canadian Cardiovascular Society (CCS), and attributable risk for myocardial infarction has been ascribed the Canadian Society of Radiologists (CSR) were included to 9 modifiable risk factors (1), clinical risk prediction in the review, with AGREE rigor scores ranging from 93% models for hard events (myocardial infarction, cardiac (most rigorous) to 21% (least rigorous). Imaging modalities death) remain suboptimal. In the United States, 40% to considered among these guidelines included resting and 60% of myocardial infarctions and sudden death occur as exercise electrocardiography, stress echocardiography, myo- unheralded first manifestations of atherosclerotic cardiovas- cardial perfusion imaging (single-positron emission com- cular disease (ASCVD) (2). puted tomography and positron emission tomography), Current U.S. guidelines for identifying and treating computed tomography (CT) and magnetic resonance an- people at increased risk for ASCVD events with proven giography, and CT coronary artery calcium scoring (CAC). therapies, such as aggressive lipid lowering and aspirin, are The authors found wide variability with regard to con- based on the Framingham Risk Score (FRS), which is sideration of these testing modalities, with most guidelines derived from several generations of long-suffering Cauca- recommending against or noting insufficient evidence for sian Red Sox fans in Massachusetts—clearly, a unique the majority of noninvasive imaging modalities, with the group. While useful and widely accepted as an office-based only positive recommendations made in reference to risk assessment tool, the Adult Treatment Panel (ATP) III intermediate-risk or selected higher-risk populations. Lo- version of the FRS has demonstrated limitations in gistic regression analysis suggested no relationships between predicting the risk of a major atherosclerotic disease the likelihood of a guideline recommending for or against event, particularly among patients with a family history of testing and the AGREE rigor score or the proportion of premature ASCVD and metabolic syndrome phenotype. guideline panelists with reported industry relationships. Misclassification of risk results in both under- and over- Hence, industry relationships did not appear to have any treatment of many persons on the basis of the current bearing on the directionality of guideline content in this ATP III guidelines (3–5). exploratory analysis. A number of noninvasive imaging modalities for assess- The only imaging modality that was addressed by a ing the degree of subclinical atherosclerosis have been majority of the included guidelines was CAC, with 10 of the 14 guidelines making specific recommendations about this modality as an adjunct to current risk prediction. Among *Editorials published in the Journal of the American College of Cardiology reflect the the intermediate-risk population, 1 guideline (CSR) made a views of the authors and do not necessarily represent the views of JACC or the favorable recommendation for use of CAC, 4 guidelines American College of Cardiology. (ACCF, AHA, NCEP, CCS) recommended consideration From the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland. The authors have reported that they have no relationships to of CAC, and 3 guidelines (USPSTF, NZGG, ACCF) disclose. found insufficient evidence to make a recommendation. The 1602 Blumenthal and Hasan JACC Vol. 57, No. 15, 2011 More Guideline Than Rule April 12, 2011:1601–3 10 guidelines were unanimous in recommending against detection of those with high ASCVD risk and whether the CAC among very low- and high-risk subjects. detection of this risk was associated with an improvement in The authors note that while there were widespread clinical outcomes (7). inconsistencies and several low AGREE rigor scores among Although 22% of subjects in this study had an abnormal the included guidelines, there was general support for myocardial perfusion imaging, only 6% of the defects were consideration of CAC among intermediate-risk subjects. moderate or large, and there was no ability to detect persons After a cogent discussion of the limitations of the present with advanced subclinical atherosclerosis without overt isch- review, Ferket et al. (6) explore the paucity of randomized emia. As a result, there was only a slightly higher rate of controlled trial (RCT) data for early detection of CAD, and coronary angiography in the group that was screened, but touch on the challenges in generating such data. there was no difference in the intensification of secondary While we agree with the authors that RCT data on this prevention measures in the screening group. Ultimately, topic is lacking, the challenges and potential pitfalls in there was no difference in clinical events between the pursuing such studies are substantial. These challenges screened and unscreened arms. One wonders if CAC testing include a large sample size and expense as well as a had been employed and identified persons with advanced complicated study design. Most would advocate randomiz- subclinical atherosclerosis for their age, it would likely have ing the study population to receive the screening test or not resulted in more appropriate use of aggressive secondary and then utilizing various intensities of lipid-lowering prevention measures, as recently demonstrated by Nasir et therapy based on how the screening test might influence al. (8) in a multiethnic population with elevated CAC perceived risk. scores. Should the basis for trial inclusion be the presence of In addition to its ability to identify persons with advanced multiple ASCVD risk factors or by FRS criteria? Should subclinical atherosclerosis for their age, the absence of CAC lipid-lowering therapy be mandated by the study protocol, has been associated with a very low risk of cardiac events and if so, what lipid-lowering algorithm should be used? over the next 5 years (9). That provides a rationale to Should such a study be placebo controlled as opposed to emphasize lifestyle changes and scale back on expensive comparing various intensities of lipid-lowering therapy? high-potency statins and focus on generic statin therapy if Given that statin therapy is now generally used aggressively the low-density lipoprotein cholesterol is Ͼ130 mg/dl by many clinicians for intermediate-risk patients even with- despite improved dietary and exercise habits. Clinicians may out imaging tests, the power to show an incremental gain also decide to refrain from ordering stress imaging tests in when adding an imaging test may prove to be limited. the setting of atypical chest discomfort. It is likely that most men over the age of 55 years and Some have suggested that one should restrict aggressive women over the age of 65 years will have some degree of pharmacotherapy to patients with at least moderate subclin- coronary calcification. Are we then obligated to treat them ical atherosclerosis to lower the number-needed-to-treat for with at least a low-dose statin and aspirin if they have below expensive pharmacotherapy. For example, in the ASCOT average CAC for their age, and use a high dose of a potent (Anglo-Scandinavian Cardiac Outcomes Trial), 93 adults statin only for those with Agatston scores Ͼ100 or for those would have needed to be treated for a mean of 3.3 years to with scores Ͼ75th percentile for their age? prevent a single cardiac event (10). Could the use of